Parker Brogdon

Parker Brogdon
Marketing Analyst at Juristat

Recent Posts

In early June, AstraZeneca approached rival drugmaker Gilead Sciences to discuss a potential merger. Though some doubt the feasibility of such a deal, this would be the biggest healthcare merger on record.
On this year’s World IP Day, WIPO Director General Francis Gurry called for a surge in green tech patenting to fight climate change. His charge follows a report that patenting for green energy technologies has slowed.
As legal tech revolutionizes the industry, offering new avenues for speed, accuracy, and quality assurance in legal work, often, one roadblock remains - the budget-minded CFO.
Biopharmaceutical companies AbbVie Inc. and Allergan recently announced that they signed a consent decree with the U.S. Federal Trade Commission that will commit the companies to sell some properties if they commence a planned merger.
Big business is all about data. We see it in almost every industry, from healthcare to financial services to aviation and beyond. But the legal industry has been slow to adapt.

Top Patent News of 2019

January 06, 2020
2020 is officially here! In order to best prepare for the new year in patent policy, let's take a look at some top stories from 2019 with a lasting impact.
Fiat Chrysler and Peugeot owner PSA Group recently announced the terms of a $48 billion merger that would create the world's fourth-largest automaker. A primary reason for the merger is to share the cost of developing electric and autonomous vehicles.
The next big technology shakeup is on its way. With a limited rollout in 2018 leading to a much more comprehensive release in 2020, 5G is here, with increased speeds, instantaneous communication, and the ability to connect just about everything.
In an update to our 2016, 2017, and 2018 lists of most difficult examiners at the USPTO, we have identified the 10 patent examiners (excluding SPEs) with the most skeptical eye toward the patent applications that cross their desks.
Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.
1 2 3

Get to know your competition.

Watch our webinar on using competitive intelligence analytics. 

DOWNLOAD

See how Juristat can transform your patent practice. 

GET A DEMO